Akari Therapeutics PLC AKTX
We take great care to ensure that the data presented and summarized in this overview for Akari Therapeutics Plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in AKTX
Top Purchases
Top Sells
About AKTX
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Insider Transactions at AKTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 31
2024
|
Raymond Prudo Chlebosz |
BUY
Grant, award, or other acquisition
|
Direct |
0
|
-
|
|
May 31
2024
|
Samir Rashmikant Patel |
BUY
Grant, award, or other acquisition
|
Indirect |
0
|
-
|
|
May 01
2024
|
Wendy F Dicicco Interim CFO |
BUY
Grant, award, or other acquisition
|
Direct |
158,473,915
+50.0%
|
-
|
|
Apr 26
2024
|
Rachelle Suzanne Jacques Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
479,569,892
+32.02%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 638M shares |
|---|